The non-vascular stents market in APAC, consisting of urinary tract, pancreatic and biliary, enteral, and airway stents, will expand in value from $148.1 million in 2013 to $223.8 million by 2021. India is set to overtake China in becoming the world’s most populous country around 2020, leading to a significant patient base and rapidly-expanding medical device market. The flexibility of manufacturers with respect to the use of stents, such as employing a pay-as-you-go model, will be hugely important in driving India’s non-vascular stent market in the future. Despite the projected demand, India’s market remains challenging for multinational corporations to penetrate, with unstable distribution networks and the prominence of low-cost manufacturers. In a country with high procedure volumes, local manufacturers can produce products at a third of multinationals’ costs, allowing them to compete directly with foreign companies.
MediPoint: Non-Vascular Stents – Global Analysis and Market Forecasts report provides analysis comprising enteral, pancreatic and biliary, airways, and urinary tract stents, across the 10 major markets up to 2021.
Questions answered in this report:
- What is the current and future outlook in the developed and emerging markets?
- What trends are affecting the global market?
- Which are the key, high growth markets that stent manufacturers should expand into?
- What non-vascular stent segments are growing the fastest?
- What is the scope for more innovation and what are the end-users looking for in their products?
- Will biodegradable stent systems fulfil these unmet needs?
- What is the physician perception and market outlook of this technology?
- What percent of global profits are from emerging markets? How will this change in the future?
Are you aware who dominates the global non-vascular stents market and which companies constitute the remainder of the market?
Report Available with Aarkstore || Published By GlobalData
Tagged: MediPoint: Non-Vascular Stents